NervGen Pharma (NASDAQ:NGEN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

NervGen Pharma (NASDAQ:NGEN) has earned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $14.00.

A number of research firms have weighed in on NGEN. Leerink Partners started coverage on NervGen Pharma in a research note on Monday, July 13th. They issued an “outperform” rating and a $10.00 price target for the company. Zacks Research upgraded NervGen Pharma to a “hold” rating in a research note on Wednesday, April 29th. Stifel Nicolaus raised NervGen Pharma to a “strong-buy” rating in a report on Thursday, April 23rd. TD Cowen assumed coverage on NervGen Pharma in a report on Thursday, June 11th. They issued a “buy” rating for the company. Finally, HC Wainwright raised shares of NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th.

NervGen Pharma Stock Performance

NervGen Pharma stock opened at $1.60 on Friday. The business’s 50-day simple moving average is $1.91. NervGen Pharma has a one year low of $1.58 and a one year high of $6.30. The firm has a market cap of $129.01 million and a P/E ratio of -17.78.

NervGen Pharma (NASDAQ:NGEN) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02).

About NervGen Pharma

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.